

2nd Long-acting Treatment and Prevention Conference

Future of antiretrovirals in Africa: Long-acting agents and beyond

29 October 2024 | Johannesburg

PROVISIONAL PROGRAMME

Start time	Topic	Proposed speaker
7:30	Arrival, registration and refreshments	
8:30	Welcome and introduction by the Conference Chairpersons	Catherine Orrell and Nosisa Sipambo
8:35	Long-acting agents - where do these products fit in the African context?	Catherine Orrell
New kids on the block: Industry Update		
8:55	Long-acting injectable cabotegravir	TBA
9:10	MK-8527 (and ISL) trials	TBA
9:25	GS-6207: long acting HIV capsid inhibitor	TBA
9:40	Q &A	All
The Future of Long acting ARVs (Treatment)		
9:50	Is injectable treatment as effective in maintaining viral suppression as standard oral ART?	Simiso Sokhela
10:10	From trial to implementation – can IMPALA help us jump across the gap?	Nigel Garrett
10:30	Tea break	
The Future of Long acting ARVs (Treatment)		
11:00	What are the treatment options for patients with multidrug-resistant HIV-1 infection?	Mohammed Rassool
11:20	What is the role of lenacapavir in future first-line HIV treatment?	Francois Venter
11:40	How long-acting injectable ART could help adolescent and young adults	Lauren Jennings
12:00	Q & A	All
The Future of Long acting ARVs (Prevention)		
12:10	Pre-exposure prophylaxis in adolescent girls and young women at risk of HIV infection	Nkosiphile Ndlovu
12:30	Uptake and retention of adolescents and young adults in differentiated HIV prevention	Maryam Shahmanesh
12:50	Panel discussion	
13:00	Lunch break	
Special populations:		
14:00	LA medications: Where do they fit in for niche populations in an African context?	Lee Fairlie
14:30	Empowering Mothers: Innovative Strategies for HIV Prevention in Pregnancy and Breastfeeding	Dvora Joseph Davey
15:00	Advancements in Neonatal HIV Therapy	Adrie Bekker
15:20	Progress towards bringing Long-acting ART to children and adolescents	Mo Archary
15:40	Q & A	All
15:50	Tea break	
Implementation: TIME FOR ACTION		
16:20	Assessing the demographic, risk profile, and clinical characteristics of early PrEP adopters	Elzette Rousseau
16:40	PrEP LA implementation in Botswana	TBA
17:00	LA implementation in Zambia	Lloyd Mulenga
17:20	South African perspective - where are with implementation, and what is the plan?	TBA
17:40	Discussion & Closing	Catherine Orrell and Nosisa Sipambo
18:00	End	